AbbVie (ABBV) Free Cash Flow (2012 - 2026)
AbbVie (ABBV) reported Free Cash Flow of $3.6 billion for Q1 2026, up 154.57% year-over-year from $1.4 billion in Q1 2025, and down 27.1% on a QoQ basis from $4.9 billion in Q4 2025.
AbbVie (ABBV) has 15 years of Free Cash Flow data on file, last reported at $3.6 billion in Q1 2026.
- Quarterly Free Cash Flow rose 154.57% year-over-year to $3.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.0 billion (up 29.87% YoY) and the FY2025 annual result came in at $17.8 billion, changed 0.09% from the prior year.
- Free Cash Flow declined to $3.6 billion in Q1 2026 per ABBV's latest filing, from $4.9 billion in the prior quarter.
- Across five years, Free Cash Flow topped out at $7.4 billion in Q3 2022 and bottomed at $1.4 billion in Q1 2025.
- The 5-year median for Free Cash Flow is $4.9 billion (2025), against an average of $5.0 billion.
- The widest annual swing landed in 2024, when Free Cash Flow plunged 66.94%; it then jumped 154.57% in 2026.
- Tracing ABBV's Free Cash Flow over 5 years: stood at $7.2 billion in 2022, then slumped by 36.96% to $4.5 billion in 2023, then jumped by 48.57% to $6.8 billion in 2024, then retreated by 27.65% to $4.9 billion in 2025, then retreated by 27.1% to $3.6 billion in 2026.
- Per Business Quant, the three latest ABBV Free Cash Flow figures stand at $3.6 billion (Q1 2026), $4.9 billion (Q4 2025), and $6.6 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | 346.00 Mn |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 3.01 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 1.47 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 3.56 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 2.93 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 1.48 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 2.43 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 2.18 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 757.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.56 Bn |
| Mar 31, 2026 | 3.56 Bn |
| Dec 31, 2025 | 4.89 Bn |
| Dec 31, 2025 | 4.89 Bn |
| Sep 30, 2025 | 6.64 Bn |
| Sep 30, 2025 | 6.64 Bn |
| Jun 30, 2025 | 4.88 Bn |
| Jun 30, 2025 | 4.88 Bn |
| Mar 31, 2025 | 1.40 Bn |
| Mar 31, 2025 | 1.40 Bn |
| Dec 31, 2024 | 6.76 Bn |
| Dec 31, 2024 | 6.76 Bn |
| Sep 30, 2024 | 5.20 Bn |
| Sep 30, 2024 | 5.20 Bn |
| Jun 30, 2024 | 2.03 Bn |
| Jun 30, 2024 | 2.03 Bn |
| Mar 31, 2024 | 3.85 Bn |
| Mar 31, 2024 | 3.85 Bn |
| Dec 31, 2023 | 4.55 Bn |
| Dec 31, 2023 | 4.55 Bn |
| Sep 30, 2023 | 7.36 Bn |
| Sep 30, 2023 | 7.36 Bn |
| Jun 30, 2023 | 6.14 Bn |
| Jun 30, 2023 | 6.14 Bn |
| Mar 31, 2023 | 4.02 Bn |
| Mar 31, 2023 | 4.02 Bn |
| Dec 31, 2022 | 7.22 Bn |
| Dec 31, 2022 | 7.22 Bn |
| Sep 30, 2022 | 7.43 Bn |
| Sep 30, 2022 | 7.43 Bn |
| Jun 30, 2022 | 4.86 Bn |
| Jun 30, 2022 | 4.86 Bn |
| Mar 31, 2022 | 4.75 Bn |
| Mar 31, 2022 | 4.75 Bn |
| Dec 31, 2021 | 4.89 Bn |
| Dec 31, 2021 | 4.89 Bn |
| Sep 30, 2021 | 7.72 Bn |
| Sep 30, 2021 | 7.72 Bn |
| Jun 30, 2021 | 4.70 Bn |
| Jun 30, 2021 | 4.70 Bn |
| Mar 31, 2021 | 4.69 Bn |
| Mar 31, 2021 | 4.69 Bn |
| Dec 31, 2020 | 4.58 Bn |
| Dec 31, 2020 | 4.58 Bn |
| Sep 30, 2020 | 5.61 Bn |
| Sep 30, 2020 | 5.61 Bn |
| Jun 30, 2020 | 2.91 Bn |
| Jun 30, 2020 | 2.91 Bn |
| Mar 31, 2020 | 3.69 Bn |
| Mar 31, 2020 | 3.69 Bn |
| Dec 31, 2019 | 3.11 Bn |
| Dec 31, 2019 | 3.11 Bn |
| Sep 30, 2019 | 4.40 Bn |
| Sep 30, 2019 | 4.40 Bn |
| Jun 30, 2019 | 2.35 Bn |
| Jun 30, 2019 | 2.35 Bn |
| Mar 31, 2019 | 2.91 Bn |
| Mar 31, 2019 | 2.91 Bn |
| Dec 31, 2018 | 3.27 Bn |
| Dec 31, 2018 | 3.27 Bn |
| Sep 30, 2018 | 4.24 Bn |
| Sep 30, 2018 | 4.24 Bn |
| Jun 30, 2018 | 2.75 Bn |
| Jun 30, 2018 | 2.75 Bn |
| Mar 31, 2018 | 2.53 Bn |
| Mar 31, 2018 | 2.53 Bn |
| Dec 31, 2017 | 2.40 Bn |
| Dec 31, 2017 | 2.40 Bn |
| Sep 30, 2017 | -112.00 Mn |
| Sep 30, 2017 | -112.00 Mn |
| Jun 30, 2017 | -113.00 Mn |
| Jun 30, 2017 | -113.00 Mn |
| Mar 31, 2017 | 2.01 Bn |
| Mar 31, 2017 | 2.01 Bn |
| Dec 31, 2016 | 1.43 Bn |
| Dec 31, 2016 | 1.43 Bn |
| Sep 30, 2016 | 1.34 Bn |
| Sep 30, 2016 | 1.34 Bn |
| Jun 30, 2016 | 1.79 Bn |
| Jun 30, 2016 | 1.79 Bn |
| Mar 31, 2016 | 2.01 Bn |
| Mar 31, 2016 | 2.01 Bn |
| Dec 31, 2015 | 1.82 Bn |
| Dec 31, 2015 | 1.82 Bn |
| Sep 30, 2015 | 2.03 Bn |
| Sep 30, 2015 | 2.03 Bn |
| Jun 30, 2015 | 1.72 Bn |
| Jun 30, 2015 | 1.72 Bn |
| Mar 31, 2015 | 1.44 Bn |
| Mar 31, 2015 | 1.44 Bn |
| Dec 31, 2014 | -731.00 Mn |
| Dec 31, 2014 | -731.00 Mn |
| Sep 30, 2014 | 1.61 Bn |
| Sep 30, 2014 | 1.61 Bn |
| Jun 30, 2014 | 1.58 Bn |
| Jun 30, 2014 | 1.58 Bn |
| Mar 31, 2014 | 487.00 Mn |
| Mar 31, 2014 | 487.00 Mn |
| Dec 31, 2013 | 1.09 Bn |
| Dec 31, 2013 | 1.09 Bn |
| Sep 30, 2013 | 1.67 Bn |
| Sep 30, 2013 | 1.67 Bn |
| Jun 30, 2013 | 1.92 Bn |
| Jun 30, 2013 | 1.92 Bn |
| Mar 31, 2013 | 1.10 Bn |
| Mar 31, 2013 | 1.10 Bn |
| Dec 31, 2012 | 846.00 Mn |
| Dec 31, 2012 | 846.00 Mn |
| Sep 30, 2012 | 2.27 Bn |
| Sep 30, 2012 | 2.27 Bn |
| Jun 30, 2012 | 1.47 Bn |
| Jun 30, 2012 | 1.47 Bn |
| Mar 31, 2012 | 1.43 Bn |
| Mar 31, 2012 | 1.43 Bn |